tirzepatide osa approval The FDA has expanded the of Eli Lilly's obesity medication Zepbound to include treating moderate to severe obstructive sleep apnea for people with obesity — the first medication approved for the Diabetes drug resolves sleep apnea

Semaglutide works by slowing stomach emptying and signaling fullness to your brainbut exceeding your prescribed dose amplifies these effects beyond therapeutic benefit, potentially causing acute gastrointestinal distress and metabolic instability

They play key regulatory roles there

Always discuss potential benefits and risks with your doctor before starting treatment

Many patients beginning tirzepatide worry about dosing logistics and meal timing because appetite and nausea changes are common

Roughly half of covered Ro members pay $50/month or less on medication

Access can be challenging for patients without a drug plan, as treatment with naltrexone or acamprosate costs approximately $1,800 annually